<DOC>
	<DOC>NCT00192803</DOC>
	<brief_summary>This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) antagonist, Candesartan. This study will provide a closer insight to the possible involvement of the renin-angiotensin system (RAS)-related enzymatic components in development or attenuation of vascular pathogenesis.</brief_summary>
	<brief_title>Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Signed informed consent Nonsmokers Type II DM diagnosed patients Blood pressure &lt; 135/90 Serum HbA1C &gt; 7% Serum creatinine &lt; 1mg% Urine microalbumin &lt; 300 mg/day Body mass index (BMI) &lt; 35 kg/m2 Insulindependent diabetic patients Patient with persistent microalbuminuria Patient with history of severe hypertension Congestive heart failure Patient receiving reninangiotensinaldosterone system (RAAS)related antihypertensive medications. Patient with major hepatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>niddm</keyword>
	<keyword>ace2</keyword>
	<keyword>NIDDM patients</keyword>
</DOC>